INVALID TRIAL
Both CHIA and your personal trial have the following criteria:
╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                  │ CHIA Criteria                                      │   Score │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╪═════════╡
│ Phase 2a Inclusion                                 │ Phase 2a Inclusion                                 │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Prior treatment for lymphoid malignancy for        │ Prior treatment for lymphoid malignancy for        │     100 │
│ progressive /refractory disease                    │ progressive /refractory disease                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Ability to provide diagnostic reports              │ Ability to provide diagnostic reports              │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ General Inclusion                                  │ General Inclusion                                  │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Active infection requiring systemic treatment      │ Active infection requiring systemic treatment      │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Major surgery within 4 weeks                       │ Major surgery within 4 weeks                       │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Breastfeeding or pregnant (intention to become)    │ Breastfeeding or pregnant (intention to become)    │     100 │
│ females or participation in other clinical trials  │ females or participation in other clinical trials  │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ For CTCL: (total skin electron beam therapy        │ For CTCL: (TSEBT) within 12 weeks, or initiation   │      87 │
│ \[TSEBT\]) within 12 weeks, or initiation of       │ of topical steroid, nitrogen mustard, or topical   │         │
│ topical steroid, nitrogen mustard, or topical      │ retinoid within 2 weeks. (Stable topical ≥ 4 weeks │         │
│ retinoid within 2 weeks. Stable topical regimen    │ prior to Day 1 allowed)                            │         │
│ for ≥4 weeks prior to Day 1 allowed                │                                                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Prior monoclonal antibody (including alemtuzumab), │ Prior monoclonal antibody, radioimmunoconjugate,   │      89 │
│ radioimmunoconjugate, antibody drug conjugate,     │ antibody drug conjugate, phototherapy,             │         │
│ phototherapy, radiotherapy, chemotherapy,          │ radiotherapy, chemotherapy, immunotherapy,         │         │
│ immunotherapy, immunosuppressive therapy, or any   │ immunosuppressive therapy, or any test agent       │         │
│ test agent within 3 weeks of Day 1                 │ within 3 weeks or for alemtuzumab 8 weeks of Day 1 │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Received B-cell receptor (BCR) and/or BCL2         │ Received BCR and/or BCL2 inhibitors were           │      90 │
│ inhibitors and were intolerant or had              │ intolerant or had relapsed/refractory disease      │         │
│ relapsed/refractory disease afterwards             │ afterwards                                         │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Phase 1 Inclusion                                  │ Phase 2a Inclusion                                 │      91 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Significant gastrointestinal (GI) disease,         │ Significant GI disease, previous major             │      92 │
│ previous major gastric/bowel surgery, difficulty   │ gastric/bowel surgery, difficulty swallowing or    │         │
│ swallowing, or malabsorption syndrome              │ malabsorption syndrome                             │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Prior transplant with stem cell infusion within 90 │ Prior transplant with stem cell infusion 90 days   │      93 │
│ days of Day 1 or active graft-versus-host          │ or active graft-versus-host treatment within 8     │         │
│ treatment within 8 weeks of Day 1                  │ weeks of Day 1                                     │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Previous malignancies within 2 years unless        │ Previous malignancies within 2 yrs. unless relapse │      97 │
│ relapse risk is small (\<5%)                       │ risk is small (< 5%)                               │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Richter's syndrome, Burkitt's lymphoma, or         │ Richter's syndrome, Burkitt's lymphoma, or         │      99 │
│ Burkitt-like Lymphoma (transformed DLBCL from      │ Burkitt-like Lymphoma (transformed DLBCL from      │         │
│ follicular NHL are eligible)                       │ Follicular NHL are eligible)                       │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Current use of systemic steroids \>20 mg QD        │ Current use of systemic steroids >20 mg QD         │      99 │
│ prednisone (or equivalent)                         │ prednisone (or equivalent)                         │         │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╧═════════╛

Only your personal trial has the following criteria:
╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                  │ CHIA Criteria                                      │   Score │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╪═════════╡
│ Must have minimum age of 18 Years                  │ Ability to provide diagnostic reports              │      37 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Creatinine levels as specified by Investigator     │ Breastfeeding or pregnant (intention to become)    │      38 │
│                                                    │ females or participation in other clinical trials  │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Known carrier or infection for human               │ Known carrier or infection for HIV/Hep B or C. HCV │      51 │
│ immunodeficiency virus (HIV)/hepatitis B or C. If  │ ab+ must be PCR-. HBV ab+ must be HBsAg- or        │         │
│ hepatitis C virus (HCV) antibody (ab)+, must be    │ undetectable DNA                                   │         │
│ polymerase chain reaction (PCR)- to be eligible.   │                                                    │         │
│ If hepatitis B virus (HBV) ab+, must be hepatitis  │                                                    │         │
│ B surface antigen (HBsAg)- or undetectable HBV     │                                                    │         │
│ deoxyribonucleic acid (DNA) to be eligible         │                                                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Eastern Cooperative Oncology Group (ECOG) Score of │ ECOG Score of 0 or 1                               │      52 │
│ 0 or 1                                             │                                                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Bilirubin \<2.0 mg/deciliter \[dL\] (if Gilberts   │ Bilirubin < 20.0mg/dL (if Gilberts then < 2.5      │      62 │
│ then \<2.5 mg/dL) and aspartate aminotransferase   │ mg/dL) and AST/AST < 2.5 ULN                       │         │
│ (AST)/alanine aminotransferase (ALT) \<2.5\*ULN    │                                                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Measurable disease defined as: ≥1 lesion that      │ Measureable disease defined as: ≥ 1 lesion ≥ 1.5   │      66 │
│ measures ≥1.5 centimeter (cm) single dimension via │ cm single dimension via CT, CT/PET with nodal or   │         │
│ computed tomography (CT), CT/positive-emission     │ mass lesions; Quantifiable circulating tumor       │         │
│ tomography (PET) with nodal or mass lesions;       │ cells; or for Waldenström's macroglobulinemia      │         │
│ quantifiable circulating tumor cells; and for      │ presence of IgM l > 2X ULN; For CTCL: mSWAT > 0    │         │
│ CTCL: Modified Severity Weighted Assessment Tool   │                                                    │         │
│ (mSWAT) \>0                                        │                                                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Hematologic absolute neutrophil count (ANC)        │ Hematologic ANC > 1000/uL and platelet > 75,000/uL │      68 │
│ \>1000/microliter (uL) and platelet \>75,000/uL    │                                                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Chronic treatment with strong CYP3A4               │ Chronic treatment with strong CYP3A4 inhibitor/    │      70 │
│ inhibitor/inducer                                  │ inducer, acid reducing agent, Proton pump          │         │
│                                                    │ inhibitors                                         │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ • Participant at least 18 years of age with        │ Phase 1 Specific Patient at least 18yrs of age     │      72 │
│ histologically confirmed CLL/SLL or B-cell non-    │ with histologically confirmed CLL/SLL or B-cell    │         │
│ Hodgkin lymphoma (diffuse large B-cell lymphoma    │ Non-Hodgkin lymphoma (DLBCL, FL, MCL, MZL,         │         │
│ \[DLBCL\], FL, mantle cell lymphoma \[MCL\],       │ lymphoplasmacytic lymphoma)                        │         │
│ marginal zone lymphoma \[MZL\], lymphoplasmacytic  │                                                    │         │
│ lymphoma)                                          │                                                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Prior therapy with Spleen Tyrosine Kinase (SYK)    │ Prior therapy with SYK inhibitors                  │      73 │
│ inhibitors                                         │                                                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Histological evidence: FL Grade 1-3A, with         │ Histological evidence: FL Grade 1-3A/iNHL, with    │      75 │
│ relapsed or refractory disease; aggressive NHL     │ relapsed or refractory disease (iNHL includes      │         │
│ (aNHL), defined as DLBCL, FL Grade 3B, MCL, and    │ LPL/WM, MZL); aNHL, defined as DLBCL, FL Grade 3B, │         │
│ transformed NHL with relapsed disease; CLL/SLL,    │ MCL, and transformed NHL with relapsed disease;    │         │
│ peripheral T-cell lymphoma (PTCL), or cutaneous    │ CLL/SLL, PTCL, or CTCL (with MF/SS) with relapsed  │         │
│ T-cell lymphoma (CTCL) (with mycosis fungoides     │ or refractory                                      │         │
│ \[MF\]/Sézary Syndrome \[SS\]) with relapsed or    │                                                    │         │
│ refractory disease                                 │                                                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Known lymphomatous involvement of the central      │ Known lymphomatous involvement of the CNS          │      77 │
│ nervous system (CNS)                               │                                                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Persistent, unresolved National Cancer Institute   │ Persistent, unresolved NCI CTCAE v4.0 ≥ Grade 2,   │      78 │
│ (NCI) Common Toxicity Criteria for Adverse Events  │ previous drug-related toxicity (except alopecia,   │         │
│ (CTCAE) version 5.0 ≥Grade 2, previous drug-       │ erectile impotence, hot flashes, libido,           │         │
│ related toxicity (except alopecia, erectile        │ neuropathy)                                        │         │
│ impotence, hot flashes, libido, neuropathy)        │                                                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ ≥1 prior regimen (minimum 2 cycles) with antibody  │ ≥ 1 prior regimen (min 2 cycles) with antibody     │      79 │
│ conjugate/cytotoxic chemotherapy                   │ conjugate, cytotoxic chemotherapy, or TKI alone or │         │
│                                                    │ in combination                                     │         │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╧═════════╛

Only CHIA has the following criteria:
╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                  │ CHIA Criteria                                      │   Score │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╪═════════╡
│ Eastern Cooperative Oncology Group (ECOG) Score of │ Serum creatinine of < 1.5 ULN or calculated CrCl   │      37 │
│ 0 or 1                                             │ of > 50 mL/min                                     │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Known carrier or infection for human               │ Known carrier or infection for HIV/Hep B or C. HCV │      51 │
│ immunodeficiency virus (HIV)/hepatitis B or C. If  │ ab+ must be PCR-. HBV ab+ must be HBsAg- or        │         │
│ hepatitis C virus (HCV) antibody (ab)+, must be    │ undetectable DNA                                   │         │
│ polymerase chain reaction (PCR)- to be eligible.   │                                                    │         │
│ If hepatitis B virus (HBV) ab+, must be hepatitis  │                                                    │         │
│ B surface antigen (HBsAg)- or undetectable HBV     │                                                    │         │
│ deoxyribonucleic acid (DNA) to be eligible         │                                                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Eastern Cooperative Oncology Group (ECOG) Score of │ ECOG Score of 0 or 1                               │      52 │
│ 0 or 1                                             │                                                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Bilirubin \<2.0 mg/deciliter \[dL\] (if Gilberts   │ Bilirubin < 20.0mg/dL (if Gilberts then < 2.5      │      62 │
│ then \<2.5 mg/dL) and aspartate aminotransferase   │ mg/dL) and AST/AST < 2.5 ULN                       │         │
│ (AST)/alanine aminotransferase (ALT) \<2.5\*ULN    │                                                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Measurable disease defined as: ≥1 lesion that      │ Measureable disease defined as: ≥ 1 lesion ≥ 1.5   │      66 │
│ measures ≥1.5 centimeter (cm) single dimension via │ cm single dimension via CT, CT/PET with nodal or   │         │
│ computed tomography (CT), CT/positive-emission     │ mass lesions; Quantifiable circulating tumor       │         │
│ tomography (PET) with nodal or mass lesions;       │ cells; or for Waldenström's macroglobulinemia      │         │
│ quantifiable circulating tumor cells; and for      │ presence of IgM l > 2X ULN; For CTCL: mSWAT > 0    │         │
│ CTCL: Modified Severity Weighted Assessment Tool   │                                                    │         │
│ (mSWAT) \>0                                        │                                                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Hematologic absolute neutrophil count (ANC)        │ Hematologic ANC > 1000/uL and platelet > 75,000/uL │      68 │
│ \>1000/microliter (uL) and platelet \>75,000/uL    │                                                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Chronic treatment with strong CYP3A4               │ Chronic treatment with strong CYP3A4 inhibitor/    │      70 │
│ inhibitor/inducer                                  │ inducer, acid reducing agent, Proton pump          │         │
│                                                    │ inhibitors                                         │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ • Participant at least 18 years of age with        │ Phase 1 Specific Patient at least 18yrs of age     │      72 │
│ histologically confirmed CLL/SLL or B-cell non-    │ with histologically confirmed CLL/SLL or B-cell    │         │
│ Hodgkin lymphoma (diffuse large B-cell lymphoma    │ Non-Hodgkin lymphoma (DLBCL, FL, MCL, MZL,         │         │
│ \[DLBCL\], FL, mantle cell lymphoma \[MCL\],       │ lymphoplasmacytic lymphoma)                        │         │
│ marginal zone lymphoma \[MZL\], lymphoplasmacytic  │                                                    │         │
│ lymphoma)                                          │                                                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Prior therapy with Spleen Tyrosine Kinase (SYK)    │ Prior therapy with SYK inhibitors                  │      73 │
│ inhibitors                                         │                                                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Histological evidence: FL Grade 1-3A, with         │ Histological evidence: FL Grade 1-3A/iNHL, with    │      75 │
│ relapsed or refractory disease; aggressive NHL     │ relapsed or refractory disease (iNHL includes      │         │
│ (aNHL), defined as DLBCL, FL Grade 3B, MCL, and    │ LPL/WM, MZL); aNHL, defined as DLBCL, FL Grade 3B, │         │
│ transformed NHL with relapsed disease; CLL/SLL,    │ MCL, and transformed NHL with relapsed disease;    │         │
│ peripheral T-cell lymphoma (PTCL), or cutaneous    │ CLL/SLL, PTCL, or CTCL (with MF/SS) with relapsed  │         │
│ T-cell lymphoma (CTCL) (with mycosis fungoides     │ or refractory                                      │         │
│ \[MF\]/Sézary Syndrome \[SS\]) with relapsed or    │                                                    │         │
│ refractory disease                                 │                                                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Known lymphomatous involvement of the central      │ Known lymphomatous involvement of the CNS          │      77 │
│ nervous system (CNS)                               │                                                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Persistent, unresolved National Cancer Institute   │ Persistent, unresolved NCI CTCAE v4.0 ≥ Grade 2,   │      78 │
│ (NCI) Common Toxicity Criteria for Adverse Events  │ previous drug-related toxicity (except alopecia,   │         │
│ (CTCAE) version 5.0 ≥Grade 2, previous drug-       │ erectile impotence, hot flashes, libido,           │         │
│ related toxicity (except alopecia, erectile        │ neuropathy)                                        │         │
│ impotence, hot flashes, libido, neuropathy)        │                                                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ ≥1 prior regimen (minimum 2 cycles) with antibody  │ ≥ 1 prior regimen (min 2 cycles) with antibody     │      79 │
│ conjugate/cytotoxic chemotherapy                   │ conjugate, cytotoxic chemotherapy, or TKI alone or │         │
│                                                    │ in combination                                     │         │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╧═════════╛

Levenshtein Ratio of Entire trial at once: 79
Average Levenshtein Ratio of individual lines: 76.62790697674419
OverAll Ratio: 77.81395348837209
